Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H1 2018

Publisher Name :
Date: 20-Feb-2018
No. of pages: 51

According to the recently published report 'Insulin Like Growth Factor I - Pipeline Review, H1 2018'; Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) pipeline Target constitutes close to 8 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic (PyMS) cells and is effective at much lower concentrations than insulin.

It plays a role in synapse maturation. It acts as a ligand for IGF1R. It binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiates a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways. It binds to integrins ITGAV: ITGB3 and ITGA6:ITGB4. It also binds to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling.

The report 'Insulin Like Growth Factor I - Pipeline Review, H1 2018' outlays comprehensive information on the Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Preclinical and Discovery stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System and Cardiovascular which include indications Acute Ischemic Stroke, Amyotrophic Lateral Sclerosis, Breast Cancer, Cerebral Infarction (Brain Infarction), Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroblastoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Parkinson's Disease, Prostate Cancer and Solid Tumor.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

  • The report reviews Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Pipeline Review, H1 2018

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Overview
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Companies Involved in Therapeutics Development
Boehringer Ingelheim GmbH
Genervon Biopharmaceuticals LLC
Regulaxis SAS
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Drug Profiles
CIGB-845 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-610.27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-630 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-7085 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit IGF1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
xentuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Dormant Products
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Discontinued Products
Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Product Development Milestones
Featured News & Press Releases
Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS
Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published
Jan 10, 2017: Genervon Releases ALS, PD and AD Disease­ Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm
Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways
Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS
May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604
May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe
Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression
Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease
Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA
Jan 08, 2015: Genervon Announces ALS Compassionate Use Results
Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results
Jun 30, 2014: Genervon Announces Biomarker Data from GALS-001 Clinical Trial for ALS
Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS
Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Genervon Biopharmaceuticals LLC, H1 2018
Pipeline by Regulaxis SAS, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List of Figures

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • Global Cytokine Inhibitor Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 85
    The global Cytokine Inhibitor market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The development prospects of cytokine inhibitors are very broad, and these drugs have many medical applications and researches. Cytokine inhibitors can reduce The activity of cytokines, thereby inhibiting their role in immune responses and reducing The activation of immune cells and The occurrence o......
  • Global Microbial Growth Media Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 93
    Microbial Growth Media is a nutrient component required by microorganisms, containing a variety of trace elements and trace elements, such as copper, iron, zinc, cobalt, manganese, etc. The global Microbial Growth Media market was valued at US$ 8007 million in 2023 and is anticipated to reach US$ 11530 million by 2030, witnessing a CAGR of 5.3% during The forecast period 2024-2030. The market for microbial growth media is essential in microbiology and biotechnology rese......
  • Global Protein Biochip Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 92
    Protein Biochip is a small Protein array used to quickly detect a large number of unknown proteins. It works in a similar way to a DNA chip. First, a large number of known proteins (such as monoclonal antibodies) are placed on a small substrate and then exposed to and reacted with The unknown protein sample. Due to The specific binding between The antigen and The antibody, it can finally be detected by means of laser. The global Protein Biochip market was valued at US$ 145 million i......
  • Global Isothermal Nucleic Acid Amplification Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 103
    Isothermal nucleic acid amplification is referred to isothermal nucleic acid amplification technology. And in this report, we get The statistics on reagents used in isothermal nucleic acid amplification technology. Nucleic acid isothermal amplification is a newer technique that amplifies DNA or RNA specific fragment from few copies to billion-fold copies under a one temperature condition, unlike PCR amplification that needs at least 30-35 thermal cycles to accomplish The reaction. T......
  • Global Microfluidics Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 134
    According to our LPI (LP Information) latest study, the global Microfluidics market size was valued at US$ 3118.7 million in 2023. With growing demand in downstream market, the Microfluidics is forecast to a readjusted size of US$ 7707.1 million by 2030 with a CAGR of 13.8% during review period. The research report highlights the growth potential of the global Microfluidics market. Microfluidics are expected to show stable growth in the future market. However, product differentiation, re......
  • Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market Growth (Status and Outlook) 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 122
    According to our LPI (LP Information) latest study, the global Isothermal Nucleic Acid Amplification Technology (INAAT) market size was valued at US$ 6141.3 million in 2023. With growing demand in downstream market, the Isothermal Nucleic Acid Amplification Technology (INAAT) is forecast to a readjusted size of US$ 11250 million by 2030 with a CAGR of 9.0% during review period. The research report highlights the growth potential of the global Isothermal Nucleic Acid Amplification Technol......
  • Global Cytokines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 119
    According to our LPI (LP Information) latest study, the global Cytokines market size was valued at US$ 203730 million in 2023. With growing demand in downstream market, the Cytokines is forecast to a readjusted size of US$ 611910 million by 2030 with a CAGR of 17.0% during review period. The research report highlights the growth potential of the global Cytokines market. Cytokines are expected to show stable growth in the future market. However, product differentiation, reducing costs, an......
  • Global Western Blot Imagers Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 94
    According to our LPI (LP Information) latest study, the global Western Blot Imagers market size was valued at US$ 406 million in 2023. With growing demand in downstream market, the Western Blot Imagers is forecast to a readjusted size of US$ 578.4 million by 2030 with a CAGR of 5.2% during review period. The research report highlights the growth potential of the global Western Blot Imagers market. Western Blot Imagers are expected to show stable growth in the future market. However, prod......
  • Global Procalcitonin Antibody Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 125
    According to our LPI (LP Information) latest study, the global Procalcitonin Antibody market size was valued at US$ million in 2023. With growing demand in downstream market, the Procalcitonin Antibody is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Procalcitonin Antibody market. Procalcitonin Antibody are expected to show stable growth in the future market. However, product di......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs